Nuvectis Pharma (NVCT) Operating Expenses (2021 - 2026)

Nuvectis Pharma has reported Operating Expenses for 6 years, with the latest figure at $6.3 million in Q1 2026.

• Quarterly Operating Expenses rose 12.43% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.3 million (up 34.48% YoY) and the FY2025 annual result came in at $28.0 million, up 38.74% from the prior year.
• Operating Expenses fell to $6.3 million in Q1 2026 per NVCT's latest filing, from $7.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $7.8 million in Q3 2025 and troughed at $2.0 million in Q1 2022.
• A 5-year average of $5.6 million and a median of $5.9 million in 2022 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 199.25% in 2022, down 39.83% in 2022.
• Over 5 years, Operating Expenses stood at $6.8 million in 2022, then climbed by 1.3% to $6.9 million in 2023, then dropped by 6.07% to $6.4 million in 2024, then climbed by 18.11% to $7.6 million in 2025, then slipped by 17.82% to $6.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $6.3 million, $7.6 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.